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Mycobacterium tuberculosis is one of the most prevalent human pathogens causing
millions of deaths in the last years. Moreover, tuberculosis (TB) treatment has become
increasingly challenging owing to the emergence of multidrug resistant M. tuberculosis
strains. Thus, there is an immediate need for the development of new anti-TB drugs.
Proteases appear to be a promising approach and may lead to shortened and
effective treatments for drug-resistant TB. Although the M. tuberculosis genome predicts
more than 100 genes encoding proteases, only a few of them have been studied.
Aminopeptidases constitute a set of proteases that selectively remove amino acids from
the N-terminus of proteins and peptides and may act as virulence factors, essential
for survival and maintenance of many microbial pathogens. Here, we characterized a
leucine aminopeptidase of M. tuberculosis (MtLAP) as a cytosolic oligomeric metallo-
aminopeptidase. Molecular and enzymatic properties lead us to classify MtLAP as
a typical member of the peptidase family M17. Furthermore, the aminopeptidase
inhibitor bestatin strongly inhibited MtLAP activity, in vitro M. tuberculosis growth and
macrophage infection. In murine model of TB, bestatin treatment reduced bacterial
burden and lesion in the lungs of infected mice. Thus, our data suggest that MtLAP
participates in important metabolic pathways of M. tuberculosis necessary for its survival
and virulence and consequently may be a promising target for new anti-TB drugs.
Keywords: MtLAP, proteases, tuberculosis, leucine aminopeptidase, M17 metallo protease, bestatin
INTRODUCTION
Mycobacterium tuberculosis is one of the most prevalent human pathogens. In the last year, an
estimated 9.6 million people developed tuberculosis (TB) leading to 1.4 million deaths (WHO,
2016). In the last years, TB treatment has become increasingly challenging owing to the emergence
of multidrug-resistantM. tuberculosis strains (Günther, 2014). Thus, there is an immediate need for
the development of new drugs that target novel biological pathways to avoid cross-resistance. For
instance, M. tuberculosis proteases appear to be a promising approach and may lead to shortened
and effective treatments for drug-resistant TB (Roberts et al., 2013). Although the M. tuberculosis
genome predicts more than 100 genes encoding proteases, only a few of them have been studied.
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Proteolysis plays a central role in the biology of pathogens
since it has been involved in their invasion, migration, acquisition
of nutrients and evasion from inflammatory and immune
responses.
Many studies have shown the importance of these proteins
in bacterial (Ingmer and Brøndsted, 2009; Kennan et al., 2010;
Frees et al., 2013), fungal (Xu et al., 2006; Yike, 2011), protozoan
(Grellier et al., 2001; Klemba and Goldberg, 2002; Bastos et al.,
2010; Suarez et al., 2013) and viral infections (Flexner et al.,
2005; Konvalinka et al., 2015). Aminopeptidases constitute a
diverse set of proteolytic enzymes that selectively remove amino
acids from the N-terminus of proteins and peptides. Due to
this kind of activity, aminopeptidases mediate, for example, the
release of free amino acids to be used as a nitrogen source
(Gonzales and Robert-Baudouy, 1996). Alternatively, these
enzymes accomplish key steps in many activation or inactivation
pathways by liberating amino acids from the N-terminus of
self-derived proteins (Savijoki et al., 2006; Hearn et al., 2009;
Naamati et al., 2009). Therefore, aminopeptidases act as virulence
factors, essential for survival and maintenance of many microbial
pathogens (Zhang et al., 2007; Skinner-Adams et al., 2010;
Bhosale et al., 2012).
Aminopeptidases could be grouped according to the
chemical nature of the catalytic site and substrate specificity
(Rawlings and Barrett, 1993). One of the most intensively
studied set of aminopeptidases is the hexameric leucine
aminopeptidases (LAPs), which belongs to the M17 family
of metalloproteases (Matsui et al., 2006). Found in animals,
plants and microorganisms, LAPs play important roles in
diverse physiological processes such as activation or inactivation
of peptides, including neuropeptides and hormone peptides
(Flexner et al., 2005), and trimming of MHC class I associated
peptides in the endoplasmic reticulum (Naamati et al., 2009). In
microbes, M17 LAPs have a function in proteolysis and have also
acquired the ability to bind DNA (Matsui et al., 2006). Studies
of M17 family members have increased in the last years due to
their emergence as potential candidates for vaccine development
and drug target in a number of parasitic and bacterial diseases
(Acosta et al., 2008; Marcilla et al., 2008; McGowan et al., 2010;
Carroll et al., 2012; Lee et al., 2015).
Leucine aminopeptidase is conserved and predicted to be
essential for in vivo survival and pathogenicity of mycobacteria
such as M. tuberculosis, M. leprae, M. bovis, and M. avium
paratuberculosis (Ribeiro-Guimarães and Pessolani, 2007).
Furthermore, there is increasing evidence that proteases are
potential drug targets against bacterial infections such as
tuberculosis (Roberts et al., 2013).
Herein, we describe the characterization of a LAPs of
M. tuberculosis (MtLAP) as a cytosolic hexameric metallo-
aminopeptidase. Moreover, molecular and enzymatic properties,
such as susceptibility to inhibitors, lead us to classify MtLAP as a
typical member of the peptidase family M17. The aminopeptidase
inhibitor bestatin strongly inhibited MtLAP activity; in vitro
M. tuberculosis growth, macrophage infection and it also
reduced bacterial burden and lungs lesions in murine model of
tuberculosis. Thus, our data suggest that MtLAP participates in
important metabolic pathways of M. tuberculosis necessary for its
survival and virulence and consequently may be a promising drug
target.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Mycobacterium tuberculosis H37Rv was grown at 37◦C in
Middlebrook 7H9 broth supplemented with 10% oleic acid-
albumin-dextrose (OAD), 0.5% glycerol, and 0.05% Tween 80.
Escherichia coli strain XL10-gold (Stratagene) was used for
cloning and plasmid propagation. The recombinant protein was
expressed in E. coli BL21 DE3 strain (Invitrogen). E. coli strains
were maintained in Luria-Bertani (LB). Plasmid selection was
performed with addition of kanamycin (50 µg/mL) or ampicillin
(100 µg/mL) to the medium. Solid medium was prepared by the
addition of 1.5% agar to the LB medium or 7H11 supplemented
with 10% OAD.
Mice
Male specific-pathogen-free C57BL/6 or interferon-gamma
knockout (IFN-γ KO) mice aged 4–8 weeks, obtained from
the animal care facility of the Institute of Tropical Pathology
and Public Health at Federal University of Goiás (UFG), were
maintained in isolators in class 3 biosafety level (BL3) cabinets
with water and food provided ad libitum. Temperature was
monitored and maintained around 22◦C, relative humidity 60%,
and 12 h light/dark cycles. The use of mice was conducted in
accordance with the guidelines of the Brazilian Society of Animal
Science Laboratory (SBCAL/COBEA). This study was carried out
in accordance with the recommendations of Committee on the
Ethics of Animal Experiments of Universidade Federal de Goiás
(Approved protocol: 027/14).
Molecular Cloning and Recombinant
Protein Expression
Mycobacterium tuberculosis LAP gene (Rv22131) was subcloned
into PCR2.1 TOPO vector (Invitrogen) using a PCR amplified
product from the M. tuberculosis H37Rv genome. The
recombinant PCR2.1 vector was digested to release the
gene that was ligated into the pET28a expression vector
(Novagen), submitted to DNA sequencing and inserted into
the expression host E. coli BL21. Bacteria containing the
recombinant expression vector were grown at 37◦C. When
the bacterial cells reached OD600 measurements of 0.6, the
expression of the recombinant protein was induced by the
addition of isopropyl-beta-D-thiogalactopyranoside (IPTG) to a
final concentration of 0.1 mM, and the incubation continued at
20◦C during 16 h. Bacterial cells were collected by centrifugation
(10,000 × g for 5 min), and suspended in 4 mL of binding buffer
(20 mM imidazole, 0.5 M NaCl, and 20 mM Tris-HCl pH 7.9).
After sonication, cell lysate was centrifuged (20,000 × g for
15 min), and the supernatant was applied onto a resin column
(Novagen) charged with NiSO4 and equilibrated with binding
buffer. Proteins were eluted with a concentration gradient of
1http://genolist.pasteur.fr/TubercuList
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imidazole (40–000 mM) and protein concentration of the eluted
fractions was determined by Bradford protein assay. The purified
MtLAP was dialyzed against Tris-HCl pH7.5 with 250 mM NaCl
and stored in 50% glycerol at −20◦C. The purity of the protein
was analyzed by Coomassie-stained 12% SDS-PAGE.
Western Blot
H37Rv lysates and culture filtrate protein (CFP) were prepared
as previously described Correa et al. (2014). Bacterial cultures
(200 mL) were grown in Sauton media to late log phase
and then pelleted by centrifugation at 2,000 × g for 20 min.
Supernatant was transferred to a fresh tube, centrifuged again,
and then filtered through a 0.2 µm filter unit. Supernatant was
concentrated by protein acetone precipitation. Bacterial pellet
was used for H37Rv lysates by sonication. Samples were resolved
by 12% SDS-PAGE and transferred to nitrocellulose membranes.
Membranes were blocked in 5% powdered milk in PBS and
probed with the anti-MtLAP or anti-Zmp1 polyclonal serum
produced in mice, followed by incubation with the anti-mouse
IgG-alkaline phosphatase secondary antibody (Sigma–Aldrich).
Antigen-antibody complex was detected via BCIP/NBT liquid
substrate (Sigma–Aldrich).
Analytical Ultracentrifugation
Sedimentation velocity experiments were performed using a
Beckman XL-I analytical ultracentrifuge and an AN-60 TI rotor
(Beckman Coulter). The experiments were carried out at 20◦C
for MtLAP at 18.2 µM in 25 mM Tris pH 7.5, 500 mM
NaCl. A volume of 400 µL was loaded into 12 mm path
cells and centrifuged at 130,000 × g (42,000 rpm). Scans were
recorded every 3 min, overnight, at 280 nm. We used the
Sednterp software2 to estimate the partial specific volume of
the polypeptide chain,
−
v = 0.741 mL/g, the solvent density,
ρ = 1.01920 g/mL, and the solvent viscosity, η = 1.0556 mPa.s,
at 20◦C. Sedimentation profiles were analyzed by the size-
distribution analysis of Sedfit3. In Sedfit, finite element solutions
of the Lamm equation for a large number of discrete, independent
species, for which a relationship between mass, sedimentation
and diffusion coefficients, s and D, is assumed, are combined with
a maximum entropy regularization to represent a continuous
size-distribution. We used 200 collected sets of data using fitted
frictional ratio for sedimentation coefficients comprised between
0 and 45 S and a 0.68 confidence level.
Assay of Enzyme Activity
The activity of MtLAP was assayed by incubating 300 ng
of the purified enzyme with 20 µM of L-Leu-7-amido-4-
methylcoumarin (Leu-AMC), Met-AMC, Pro-AMC, Arg-AMC,
or Asp-AMC (Sigma–Aldrich) in 100 µL reaction buffer (25 mM
Tris-HCl pH 7.5 and 1.5 mM NiSO4). Substrate hydrolysis
was determined by AMC release measured fluorometrically
using SpectraMax M5 Microplate Reader with SoftMax Pro
Data Acquisition and Analysis Software (Molecular Devices) as
2http://www.jphilo.mailway.com/
3http://www.analyticalultracentrifugation.com
described previously (Cadavid-Restrepo et al., 2011). Enzyme
cation preference was performed using different concentrations
of CaCl2, CoCl2, CuSO4, FeCl2, MgCl2, MnCl2, NiSO4, or ZnSO4
in Tris-HCl pH 7.5 at 25◦C containing Leu-AMC as substrate.
The optimal pH for activity was determined as described above
in 25 mM AMT buffer (25 mM acetic acid-25 mM MES-25 mM
Tris-HCl) adjusted to pHs ranging from 5 to 10. To assess the
effect of temperature on MtLAP activity, enzyme reactions took
place at temperatures ranging from 10 to 100◦C. The Michaelis–
Menten constant (Km) of MtLAP were determined according to
the hyperbolic regression method using Prism software version
5.03 (GraphPad). The oligomeric structure of the enzyme was
evaluated by electrophoresis as described previously (Cadavid-
Restrepo et al., 2011). Briefly, purified protein was subjected to
8% SDS-PAGE in the presence 0.01% SDS under non-reducing
conditions with or without previous boiling of the sample.
MtLAP Inhibition
Different concentrations of tosyl-lysylchloromethane (TLCK),
bestatin, tosyl phenylalanyl chloromethyl ketone (TPCK), EDTA,
L-trans-epoxysuccinylleucylamido-4-guanidino butane (E-64),
phenylmethylsulfonyl fluoride (PMSF), 1,10-phenanthroline,
leupeptin, or pepstatin A were incubated with 300 ng of
purified MtLAP in 100 µL reaction buffer for 5 min at room
temperature, before the substrate was added. Enzymatic reactions
were monitored as described above. All inhibitors were from
Sigma–Aldrich. Bestatin half-maximal inhibitory concentration
(IC50) and 95% confidence interval (CI) were calculated by non-
linear regression log (inhibitor) vs. normalized response with
variable slope method.
Effect of Bestatin on M. tuberculosis
Growth
To study the effect of bestatin on M. tuberculosis growth,
bacterial cultures were adjusted, and 100 CFU were deposited
into each well of a 96-well microplate that contained a serial
dilution of bestatin, ranging from 1600 to 25 µg/mL in
Middlebrook 7H9 supplemented with 10% OAD, 0.5% glycerol
and 0.05% Tween 80. The bestatin 50% growth inhibitory
concentration (GI50) value was determined by non-linear
regression log (inhibitor) vs. normalized response with variable
slope method.
Alveolar Macrophage Culture
Alveolar macrophages were obtained from C57BL/6 mice
bronchoalveolar lavage (BAL). Mice were euthanized and the
pulmonary cavities were opened. Using an 18-gage needle, the
trachea was cannulated, and 1.0 mL of ice-cold 5 mM EDTA in
PBS was slowly injected into the lungs and then withdrawn. This
procedure was repeated five times and a total of 4 mL of BAL fluid
was collected from each mice. The single-cell suspension was
then washed and centrifuged at 1,000 × g. Red blood cells were
lysed upon 5 min incubation in 2 mL of Gey’s solution (155 mM
NH4Cl and 10 mM KHCO3) at room temperature. Macrophages
were then washed with PBS and resuspended in RPMI medium
1640 (Gibco) supplemented with 1% glutamine, 1% non-essential
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FIGURE 1 | Sequence analysis and phylogenetic relationship of M17 LAPs. (A) Multiple Carboxi-terminal portion amino acid sequence alignments of different
LAPs. Amino acid sequences from the conserved C-terminal region of LAPs were aligned by the ClustalX program. Amino acids marked in black show 50% identity
and those in gray show 50% similarity. Putative metal binding sites (∗), catalytic site (#), and M17 signature (underlined) are indicated. Sequences were obtained from
the protein database of the National Center for Biotechnology Information (NCBI). (B) Phylogenetic relationship of LAP in mycobacterial genus. 21 full length
sequences, derived from the non-reduntant (NR) protein database of the NCBI (listed in Experimental Procedures), were aligned by the ClustalX program, and the
phylogram generated with the Mega package after 1000 bootstraps inferred using the Neighbor-Joining method. The tree is drawn to scale with branch lengths in
the same units as those of the evolutionary distances used to infer the phylogenetic tree. Drawn balloons represent the sequences clusters of true pathogenic (TP),
M. tuberculosis Complex (MTC), opportunist pathogens (OP) and non-pathogenic mycobacteria (NP).
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TABLE 1 | Leucine aminopeptidases (LAPs) amino acid sequence identity.
Identity
Organism M. tuberculosis
M. bovis 0.996
M. leprae 0.824
M. avium 0.805
P. aeruginosa 0.313
H. sapiens 0.281
S. enterica 0.265
S. aureus 0.258
B. bovis 0.253
T. cruzi 0.234
P. falciparum 0.211
F. hepatica 0.149
amino acids, 1 mM sodium pyruvate, 1% penicillin-streptomycin
and 10% FBS.
M. tuberculosis Infected Macrophage
Treatment Assay
The alveolar macrophages were plated in 96 well plates
(100 µL/well) at 106 cells/well and incubated for 24 h at 37◦C.
Macrophage monolayers were then washed and incubated with
100 µL infection media (RPMI medium 1640 supplemented with
1% glutamine, 1% non-essential amino acids, 1 mM sodium
pyruvate, 10% FBS) containing 5 × 106 CFU of M. tuberculosis
H37Rv (MOI= 5) at 37◦C under CO2 for 3 h. Then the cells were
washed twice with warm PBS to remove extracellular bacteria
and supplemented with RPMI free of antibiotics and containing
a range of 0, 100, or 200 µg/mL of bestatin. Forty-eight hours
after infection, media was aspirated from infected macrophage
wells, and 100 µL of ice-cold sterile lysis solution (0.05% SDS,
w/v in H2O) was added to each well. The lysates were transferred
to a new 96 well plate for serial dilutions. Triplicate wells were
plated on 7H11 agar supplemented with OAD. The plates were
cultured in a CO2 incubator for 3–4 weeks and the number of
CFUs counted.
M. tuberculosis Infection and In vivo
Bestatin Treatment
IFN-γ knockout mice were intranasally infected with 104
M. tuberculosis H37Rv and treatment was performed as
previously described (Lenaerts et al., 2003). In brief, 1 day post
infection, three mice were euthanized by cervical dislocation to
verify bacterial uptake per mouse. Each treated group consisted
of four mice. Treatment was started 18 days after infection and
lasted up to 28 days post infection. Another three infected mice
were euthanized to determine the bacterial load at the beginning
of the treatment (day 18 post infection). Lyophilized bestatin
was dissolved in PBS and 100 µL administered by intranasal
instillation in eight treatments for 5 days/week at 1 mg/kg of
body weight while Isoniazid (INH) was administered at 25 mg/kg
as positive control. A negative control group of infected but
untreated mice received 100 µL of intranasal PBS. After the
cessation of treatment (day 28 post infection), viable bacteria
in the mice lungs were evaluated. Right and left cranial lung
lobes were removed and homogenized in PBS containing 0.05%
Tween 80, and tissue homogenates were serially diluted in PBS
and plated in duplicate onto Middlebrook 7H11 agar. Colonies
were counted after 3–4 weeks of incubation at 37◦C in a 5% CO2
incubator.
Histopathology
The caudal left lung lobe was excised from all animals, stored
in 10% formalin, then embedded in paraffin and sections were
prepared and stained with hematoxylin and eosin (H&E). Lung
lesions were determined using the measurement tool in the
AxioVision software (Carl Zeiss). Total lesion area was calculated
by the sum of all areas of lesions in a lung section per mouse.
Statistical Analysis
Statistical significance between groups was determined by the
two-tailed unpaired Student’s t-test or One-way ANOVA with
Dunnett or Tukey post-test using Prism software version 5.03
(GraphPad).
RESULTS
LAP Is Conserved in Pathogenic
Mycobacteria
The sequencing of M. tuberculosis H37Rv genome revealed
a small number of genes coding for putative peptidases that
mediate aminopeptidolytic activities https://merops.sanger.ac.
uk/index.shtml. We identified only one copy of a putative LAP
gene (Rv22134), which has thus far not been characterized.
Rv2213 is an open reading frame (ORF) that encodes a protein
of 515 amino acids. Multiple amino acid sequence alignments
revealed that the C-terminal conserved region presents the
typical signature sequence NTDAEGRL of the M17 family
(Burley et al., 1990) as well as multiple conserved amino acids
within predicted functional domains for metal binding and
catalytic activity conserved across different taxa (Figure 1A). LAP
of M. tuberculosis shares high identity with other pathogenic
mycobacterial LAPs, over 80% with M. leprae, M. bovis, and
M. avium paratuberculosis. Although it contains conserved
functional domains, MtLAP shares less than 32% identity with
species out of the Mycobacterium genus, diverging from LAPs
from other bacteria, protozoa and higher eukaryotes, including
only 28.1% identity with human LAP (Figure 1A and Table 1).
The phylogenetic analysis of LAP from the Mycobacterium genus
shows a relationship between LAP sequence similarities and
bacterial physiology and pathogenesis. The phylogenetic tree
shows divergent groups of proteins that cluster according to
the bacterial rate of growth and pathogenicity with a strong
bootstrap support (Figure 1B). Sequences are divided in two
defined clades; one branch includes slow growing mycobacteria
and the other cluster, the rapid growers. Moreover, for slow and
rapid growing mycobacteria, LAP sequences are divided into
4http://tuberculist.epfl.ch
Frontiers in Microbiology | www.frontiersin.org 5 March 2017 | Volume 8 | Article 504
fmicb-08-00504 March 23, 2017 Time: 16:39 # 6
Correa et al. M17 Metallo-Aminopeptidase of Mycobacterium tuberculosis
FIGURE 2 | Purification and subcellular localization of M. tuberculosis
LAP (MtLAP). (A) Purification of recombinant MtLAP: IPTG-induced MtLAP
was purified by nickel affinity chromatography. Aliquots of resin unbound
fraction (NB), molecular mass marker (M), wash (W) and elution with
increasing imidazole concentration were submitted to 12% reducing
SDS-PAGE and the gel stained with Coomassie brilliant blue. Arrowhead
indicates LAP position at 55 kDa. (B) Localization of MtLAP by immunoblot
analysis (up) and control of non-specific lysis (down). Lanes: H37Rv pellet total
cell lysate (Pellet) and H37Rv culture filtrate proteins (CFP) were probed with
MtLAP or Zmp1 (Control) polyclonal mouse antiserum. (C) Analysis of MtLAP
oligomeric state: the recombinant enzyme was subjected to 8% SDS-PAGE in
the presence of only 0.01% SDS, previously boiled (2) or not (1). Arrowheads
indicate 100 kDa and over 220 kDa oligomeric states.
three groups. One branch includes true pathogenic mycobacteria
(TP), another branch groups opportunistic bacteria (OP) and
the other branch contains non-pathogenic mycobacteria (NP).
Similarly, true pathogenic slow growing mycobacteria belong
to the M. tuberculosis complex (MTC) grouped together in a
very close phylogenetic clade (Figure 1B). These findings suggest
that MtLAP may be involved in physiological and pathogenicity
processes in tuberculosis, thus predicted to be essential for in vivo
survival and pathogenicity (Ribeiro-Guimarães and Pessolani,
2007).
MtLAP Is an Oligomeric Cytosolic
Protein
To establish the kinetic parameters of MtLAP, the Mycobacterium
tuberculosis gene Rv2213 was cloned into the prokaryotic
FIGURE 3 | Sedimentation velocity experiments of purified MtLAP.
(A) MtLAP experimental sedimentation profile at 18.2 µM in 25 mM Tris pH
7.5, 500 mM NaCl obtained at 280 nm at 130,000 × g, at 20◦C, in 12 mm
cell and their modeled profiles with the c(s) analysis (upper panel). The
corresponding residual, superposition of the differences between the
experimental and fitted curves (lower panel). (B) Result of the c(s) analysis for
LAP at 18.2 µM.
expression vector pET28a. The recombinant protein was
expressed and purified by nickel affinity chromatography
under non-denaturing conditions with increasing imidazole
concentrations. SDS-PAGE analysis revealed a strong band, with
high purity, eluted with imidazole at a concentration higher
than 200 mM, corresponding to the expected protein molecular
mass of approximately 55 kDa (Figure 2A). For detection
and identification of the native protein, anti-MtLAP polyclonal
serum was produced in mice. We verified by western blot the
presence of the protein in the H37Rv cell fraction extract, but
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FIGURE 4 | Biochemical characterization of MtLAP. (A) Effect of metal ions on MtLAP activity: Activity was assayed in the presence of different metal ions
(1.5 mM concentration) and no metal addition (-). (B) Effects of pH on MtLAP activity: the experiments were performed over the pH range 5–10 in 25 mM AMT buffer
with 1.5 mM NiSO4 and 20 µM substrate. (C) Effects of temperature on MtLAP activity: the experiments were carried out in 25 mM Tris–HCl buffer pH 7.5 over a
temperature range of 10–100 ◦C with 1.5 mM NiSO4 and 20 µM substrate. (D) Activity of MtLAP against different amino acids: the experiments were carried out in
25 mM Tris–HCl buffer pH 7.5 with 1.5 mM NiSO4 and 20 µM of each indicate substrate. Data shown represent mean ± SEM, relative to maximal activity obtained,
n = 3.
not in the culture supernatant (CFP, Figure 2B). To confirm
that MtLAP was not released to the supernatant, mycobacterial
metalloprotease Zmp1, previously described as a secreted protein
(Master et al., 2008; Correa et al., 2014), was detected in the
same culture supernatant preparations (Figure 2B). Since LAPs
exist naturally as oligomeric-dependent active proteases (Matsui
et al., 2006), we decide to test MtLAP oligomerization. Therefore,
non-boiled nor reduced purified protein was subjected to 8%
SDS-PAGE in the presence of 0.01% SDS. Bands about 100 kDa
and over 220 kDa were detected indicating an oligomeric protein
complex, although the 55 kDa monomer was predominant in
gel (Figure 2C, lane 1). Sample boiling resulted in complete
monomerization of MtLAP (Figure 2C, lane 2).
MtLAP Assembles into a Homohexamer
The results obtained from sedimentation velocity experiments
corroborate the calibrated exclusion size chromatography
findings. The experimental and fitted sedimentation velocity
profile of MtLAP (Figure 3A) obtained at 18.2 µM shows a
major species, approximately 70% of the signal, that sediments
at 11.2 S (S20,w = 12.6 S). The s-value is directly related to the
molar mass (M) and the Stokes radius (RS) of the particle. The
combination of the s-values with RS = 5.9 nm estimated from
calibrated size exclusion chromatography gives an estimate for
the MtLAP complex of M = 323 kDa, which is close to the
expected molecular mass for a hexamer (334.4 kDa). Considering
a hexamer, the RS value corresponds to a frictional ratio of
1.30, a value close to 1.25 that relates to globular proteins. It
suggests that the MtLAP hexamer has a globular shape. Larger
species were also detected but a well-defined peak was difficult to
identify. The larger species most probably represents aggregates
due to sample aging and also to the fact that MtLAP was prone
to precipitate even in high ionic strength buffers. The smaller
peaks correspond to only less than 8% of the signal and give
estimated masses of 64 and 140 kDa, close to the expected
mass of a monomer and a dimmer, respectively (Figure 3B).
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FIGURE 5 | MtLAP inhibition pattern. (A) Effect of different inhibitors on the
activity of MtLAP: the experiments were performed in 25 mM Tris–HCl buffer
pH 7.5 with 1.5 mM NiSO4, 20 µM of Leu-AMC and different inhibitors
(10 mM EDTA, 10 mM phenantroline, 30 µM bestatin, 5 mM PMSF, 100 µM
TPCK, 5 µM E64, 500 µM TLCK, 25 µM pepstatin A and 100 µM leupepsin).
Data represent % of the activity measured without inhibitors. (B) Bestatin
inhibits the enzymatic activity of MtLAP in a dose-dependent manner: the
experiments were carried out by pre-incubation of MtLAP with different
concentrations of bestatin. Curve fit by non-linear regression log (inhibitor) vs.
normalized response with variable slope method.
The presence of these smaller forms may be related to the
high salt concentration in the buffer. These data clearly indicate
that active MtLAP is an oligomeric protein formed by six
monomers.
LAP of M. tuberculosis Is a Metal
Dependent Protease
The activity of recombinant MtLAP was determined
by measuring the fluorescence of AMC (7-amido-4-
methylcoumarin) released by hydrolysis of the enzyme substrate
Leu-AMC. However, in the initial assays, no MtLAP activity
was observed when the enzyme was incubated with substrate
in Tris-buffer in the absence of metal ions. As MtLAP belongs
to the metallo aminopeptidase M17 family, that has a broad
range of preferences for metal ions, we decided to test MtLAP
metal dependence. The enzyme did show activity when the assay
was conducted in the presence of metal ions including Co2+,
Mg2+, Mn2+, Ni2+, and Zn2+. Conversely, Ca2+, Cu2+, and
Fe2+ could not activate MtLAP. The maximum activity was
observed in the presence of 1.5 mM Ni2+, followed by Mn2+,
Co2+, Zn2+, and Mg2+ (Figure 4A). Regarding pH dependence,
its optimal activity was observed at pH 7.5. Although at acidic
pHs the enzyme rapidly loses activity and no substrate cleavage
was observed at pH 5, the enzyme was resistant to alkaline
environment displaying about 50 and 25% of its maximal activity
at pH 9 and 10, respectively (Figure 4B). The activity of MtLAP
was determined at different temperatures in the range of 10 –
100◦C. At 37◦C, the enzyme showed 70.78% of its maximal
activity measured at 50◦C (Figure 4C). To assess the enzyme
substrate preference, MtLAP was incubated with aminopeptidase
substrates (Figure 4D). Calculated Km values are 69.4 ± 3.6 µM
for Leu-AMC, 61.8 ± 4.4 µM and 344.8 ± 49.2 µM for Met-
AMC and Pro-AMC, respectively (Supplementary Figure 1).
The enzyme showed maximal activity on substrates with
hydrophobic amino acids leucine and methionine. Low activity
was observed with the non-polar cyclic amino acid proline
based substrate. No cleavage was detected on substrates with
charged side chains containing arginine and aspartic amino acid
residues.
MtLAP Inhibition Pattern
Enzyme hydrolytic activity was not sensitive to the classical
serine (PMSF, TLCK or TPCK) and cysteine (E-64) protease
inhibitors. The enzyme was not inhibited by leupeptin, an
inhibitor of cysteine/serine/threonine proteases, nor by pepstatin
A that inhibits aspartyl proteases. The chelating agents 1,10-
phenanthroline and EDTA inactivated 86.5 and 68% of the
enzyme activity, respectively. Furthermore, the enzymatic activity
of MtLAP on Leu-AMC was completely inhibited by 30 µM
bestatin (Figure 5A). Since bestatin is a potent inhibitor of
LAPs, we assayed its inhibition on MtLAP activity in a range of
0.01–100 µM using Leu-AMC as a substrate (Figure 5B). As a
result, the calculated IC50 was 53.78 nM as shown in Figure 5B
with 95% CI of 46.44–62.28 nM.
Bestatin Inhibits M. tuberculosis Growth
in In vitro and Ex vivo
Since bestatin is efficient at inhibiting MtLAP activity, we asked
if it could constrain M. tuberculosis growth. To address this
question, we cultivated the bacteria in liquid media with different
concentrations of bestatin and measured CFUs. At day seven of
culture, a dose-dependent manner inhibition of M. tuberculosis
growth was observed (Figure 6A). Bestatin shows a 50% growth
inhibitory concentration value (GI50) of 174.2 µg/mL (95% CI
143.1–212.0 µg/mL). We next examined the effect of bestatin
on M. tuberculosis survival inside macrophages. The bestatin
treatment done after M. tuberculosis alveolar macrophages
infection showed a significant dose-dependent reduction in
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FIGURE 6 | Bestatin inhibits growth of M. tuberculosis in vitro and during macrophage infection. (A) Bestatin inhibits the growth of M. tuberculosis in vitro
in a dose-dependent manner: M. tuberculosis was incubated with or without (PBS) different concentrations of bestatin at 37◦C, and growth was monitored 7 days
after addition of the inhibitor by plating serial dilution of culture and counting CFUs. (B) M. tuberculosis survival in macrophages: After macrophage infection, bestatin
or PBS was added to the culture and viable M. tuberculosis was determined by CFU counting relative to the PBS group 48 h after treatment. Data shown represent
mean ± SEM, n = 3. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; difference from PBS group by One-way ANOVA with Dunnett post test.
colony counts. Compared to PBS infection control, 29.8% of the
mycobacteria were recovered using 200 µg/mL of inhibitor and
46.4% of the bacteria were viable using bestatin at 100 µg/mL
(Figure 6B). Those results suggest that the activity of LAP may
be essential for M. tuberculosis survival and virulence.
Bestatin Reduces In vivo Bacterial
Burden and Lung Lesions
Bestatin has been used before as a low molecular
immunomodulator. It exhibits antitumoral and antimicrobial
activities through the activation of host defense mechanisms
and shows low toxicity even after a long-term administration
(Ota, 1991). In several mouse-model studies, effective and safe
bestatin doses ranged from 0.1 to10 mg/kg of body weight
or in doses of 10–100 µg per animal (Bruley-Rosset et al.,
1979; Carter et al., 2012; Reinhoudt et al., 2012; Lis et al.,
2013). To test whether bestatin has any effect on tuberculosis
progression, IFN-γ knockout mice were infected with 104 CFU
of M. tuberculosis H37Rv and treated with the inhibitor at
1 mg/kg/day intranasally. After completion of therapy, bestatin
reduced bacterial burden (∼1.4 Log) in the lungs when compared
to PBS administration and isoniazid corroborates the efficacy of
treatment method (Figures 7A,B). Thus, bestatin inhibits up to
95.37% of M. tuberculosis growth in the mice lungs. In addition,
treatment reduced lung lesions caused by infection (Figure 7C)
from 9.09 mm2 of lung lesion area in PBS group to 2.46 mm2 in
bestatin treated mice (Figure 7D). Taken together, our results
indicate that bestatin is a promising drug and a model compound
for anti-TB drugs.
DISCUSSION
Leucine aminopeptidases are known to play important roles
in bacterial physiology and have not yet been characterized
in many pathogenic bacteria, including M. tuberculosis. In
this study we report the identification and biochemical
characterization of the M. tuberculosis M17 family LAP
as a cytosolic metal-dependent protease that shows high
sensitivity to bestatin. In addition, M. tuberculosis in vitro
growth and survival in macrophages had a significant bestatin
dose-dependent reduction. Furthermore, bestatin treatment
in murine tuberculosis model was useful in reducing both
mycobacterial load in the lungs and tissue lesions caused the
infection.
Aminopeptidases are widely distributed in animals, plants
and microorganisms, and found in the extracellular millieu,
cytoplasm, in many subcellular organelles and as components
of membranes (Matsui et al., 2006). M17 protease members
produced by a number of pathogenic organisms are currently
under intense investigation. In some of these cases, the enzyme
is secreted and act extracellularly. However, bacterial LAPs are
most commonly found in the cytosol and generally act as homo-
hexameric enzymes, while extracellular LAPs are functional as
monomers (Gonzales and Robert-Baudouy, 1996). In agreement
with literature, we found that the M. tuberculosis LAP is
cytosolic (Figure 2B) and probably acts as an oligomer enzyme
(Figure 2C) formed by six monomers (Figure 3). The enzyme
could otherwise be secreted in vivo under specific physiological
conditions.
Leucine aminopeptidases belong to the M17 family of
metalloproteases, which mainly prefer Zn2+, while other
aminopeptidases are dependent on Mn2+, Fe2+, or Mg2+. Like
that of Staphylococcus aureus (Singh et al., 2012), M. tuberculosis
LAP exhibits maximum activity in the presence of Ni2+, but
it is active in the presence of a broad range of other metals
(Figure 4A). The wide-ranging metal cofactor profile of LAP may
allow its activity under different in vivo conditions, where some
metals are limited and tightly regulated by both host and bacteria,
resulting in an altered enzymatic activity under certain conditions
(Kehl-Fie et al., 2011; Hood and Skaar, 2012).
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FIGURE 7 | Bestatin reduces in vivo M. tuberculosis burden and lung lesion. (A) IFN-γKO mice were intranasal infected with 104 CFU of M. tuberculosis
H37Rv. Eighteen days after infection, the mice were treated with bestatin at 1 mg/kg () isoniazid (N) and control group of infected mice were treated with PBS ( ).
The bacillary loads in the lungs were determined after euthanizing the mice at days 1, 18, and 28 post infections. (B) Comparison of lung CFU after treatment.
(C) Representative lung sections (left bottom lobe) with HE stain of M. tuberculosis infected mice treated with PBS (left) or bestatin (right). Scale bars represent
200 µm. (D) Results of the quantification of the inflammatory lesion area sizes. Data shown represent mean ± SEM, n = 4. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001;
difference between groups by One-way ANOVA with Tukey’s Multiple Comparison Test or t-test.
Despite conservation of amino acid sequences, M17 members
show variable pH and temperature optima. Although MtLAP is
active over a broad range of temperatures with optimal 55◦C, at
physiological temperature the enzyme remains with high activity
(Figure 4C). Moreover, its activity shows a marked dependence
on neutral/alkaline pH, since the enzyme is completely inactive
at pH 5 (Figure 4B). This correlates well with observations
that recombinant members of M17 proteases assemble better
into active oligomers at higher temperature and alkaline pHs
(Matsui et al., 2006; Cadavid-Restrepo et al., 2011). Thus, the
ability of M. tuberculosis to preserve intrabacterial pH inside
phagosomal compartments (Vandal et al., 2008) provides an
optimum environment for MtLAP function during infection.
MtLAP does cleave substrates with charged side chains and
shows preference for substrates with hydrophobic amino acids
(Figure 4D). This substrate specificity profile supports future
search for specific inhibitors of M. tuberculosis LAP, which could
be used as new TB drugs.
Bestatin is a natural dipeptide analog product isolated from
actinomycetes. It potently inhibits aminopeptidases, including
LAP M17 family (Suda et al., 1976; Burley et al., 1991; Matsui
et al., 2006), and MtLAP shows high sensitivity to this inhibitor
(Figures 5A,B). Bestatin inhibited MtLAP enzymatic activity
as well as M. tuberculosis in vitro growth, suggesting that
MtLAP activity is associated to metabolism and physiology of
the bacteria (Figure 6A). Moreover, bestatin has been shown
to inhibit in vitro growth of S. aureus (Singh et al., 2012) and
Babesia bovis (Aboge et al., 2015), as well as P. falciparum in
mouse models of malaria (Nankya-Kitaka et al., 1998; Gavigan
et al., 2001; Naughton et al., 2010). The reduction mediated
by bestatin of bacterial burden and lung tissue lesions lead
by infection, (Figure 7), suggests MtLAP may act not only
in bacterial physiology but also in M. tuberculosis virulence.
These results support further experiments to establish the role
of MtLAP in the pathogenesis of TB. Bestatin is associated with
immunomodulatory effects activating monocytes/macrophages
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and promoting the secretion of the pro-inflammatory cytokines
IL-1, IL-6, IFN-γ, and TNF-α, as well as the growth factors
GM-CSF and G-SCF by immune system cells (Müller et al.,
1982; Schorlemmer et al., 1983; Shibuya et al., 1987; Okamura
et al., 1990). It has been demonstrated that bestatin can be
administered to animals at very low toxicity and with multiple
positive effects on the immune system. Those studies have also
revealed beneficial effects on the survival of animals with some
experimental tumors. Subsequent research in human patients
have confirmed the immunomodulatory effects of bestatin and
provided encouraging results on the potential of this drug in
cancer treatments (Talmadge et al., 1986; Inoi et al., 1995).
Bestatin is used as an immunomodulator and antitumor drug,
under the trademark Ubenimex and various active stereoisomers
and substituted analogs are commercially available as useful tools
for in vitro and animal drug experimentation (Ota, 1991; Scornik
and Botbol, 2001). Moreover, bestatin may have effects direct on
bacteria and/or in modulation of host immune system leading
to bacterial control. Thus, more studies are needed to establish
whether bestatin mechanism of action actually correlates with
mycobacterial proteins beyond LAP or even with host enzymes.
In toxicological studies, bestatin showed very low toxicity
and no death occurred following the oral administration of
the maximum dose capable of dosing such as 4 g/kg for mice,
2 g/kg for rats and 1.2 g/kg for dog. General toxic signs seen
in mice and rats following subcutaneous and intraperitonial
injections were depression, suppressed movement, piloerection,
inhibition of spontaneous movement, anorexia and emaciation
(Sakakibara et al., 1983). In human clinical studies of bestatin,
hematology, hepatic and renal function tests revealed no apparent
adverse reactions and minimal side effects were noted chiefly
comprising of reversible gastro-intestinal disturbances (Saito
et al., 1983; Ikeda et al., 1985; Tsukagoshi, 1987; Ichinose
et al., 2003). Although bestatin properties seem to be promising,
pharmacokinetics could be an obstacle to its use as a TB drug.
In mice, 3H-bestatin diffuses rapidly from the intravascular space
into the extracellular fluid after its intravenous injection and
from there most of the drug is eliminated in the urine (Scornik
and Botbol, 1997). Furthermore, bestatin, orally administered,
is efficiently absorbed by the intestinal brush border, whereas
high concentrations of the drug in the serum are maintained
only for a short time in mice because of its rapid elimination
(Abe et al., 1989). Otherwise, urinary elimination is slower
in humans (Ueda et al., 1994). Moreover, intrapulmonary
delivery of isoniazid, capreomycin, or amikacin to mice has
resulted in a better reduction of pulmonary mycobacterial
loads than that seen by standard drug delivery methods when
lower concentrations of drugs and fewer doses have been
used (Gonzalez-Juarrero et al., 2012; Pham et al., 2015). Thus,
in our study, intranasal administration of bestatin may have
extended drug effects in the lungs, the main TB target organ,
bypassing the problem of its rapid urinary elimination and
thus showing efficacy to reduce M. tuberculosis loads in mice
lungs. The bacterial counts in infected mice indicates that
bestatin probably has in vivo bacteriostatic activity since it has
maintained the pulmonary bacterial load constant during the
time course of the treatment whereas isoniazid decreases the
M. tuberculosis burden in the mice lungs (Figure 7A). Taking
the above facts with our findings, bestatin or its analogs that
show/have better pharmacokinetics could be promising drugs on
TB treatment.
In summary, our results showed that M. tuberculosis produces
an oligomeric cytosol LAPs that is a member of the M17
metalloprotease family. The activity of M. tuberculosis LAP is
very sensitive to bestatin, a powerful aminopeptidase inhibitor.
In addition, bestatin effects on mycobacterial growth and TB
mice model infection highlight aminopeptidases as potential drug
targets in tuberculosis.
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